# VOXZOGO (vosoritide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vosoritide

> The PDUFA target action date for VOXZOGO (vosoritide), sponsored by BIOMARIN PHARMACEUTICAL INC (BMRN), is February 28, 2027, for achondroplasia. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the VOXZOGO (vosoritide) PDUFA date?

The PDUFA target action date for VOXZOGO (vosoritide), sponsored by BIOMARIN PHARMACEUTICAL INC (BMRN), is February 28, 2027, for achondroplasia. Status: scheduled. SEC Form 10-Q: "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." Last confirmed November 3, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/vosoritide)

Source: SEC Form 10-Q, accession 0001048477-26-000023, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/vosoritide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | VOXZOGO (vosoritide) |
| Codes | BMN-111 |
| Sponsor | BIOMARIN PHARMACEUTICAL INC (BMRN) https://sec-api.dev/companies/bmrn/catalysts |
| Indications | [achondroplasia](https://sec-api.dev/indications/achondroplasia), [hypochondroplasia](https://sec-api.dev/indications/hypochondroplasia), hch, the first potential targeted therapy for the condition, Idiopathic Short Stature, Noonan Syndrome |
| Modality | peptide |
| FDA designations | none disclosed |

## Timeline

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-05-01, last confirmed 2025-08-04.
- Press release filed with the SEC (EX-99) (accession 0001048477-25-000088): "With VOXZOGO in hypochondroplasia, the company expects to share topline data from its pivotal study in the first half of 2026 and file submissions to global health authorities for approval in the second half of 2026, leading to a potential launch in 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-25-000088): "(iii) expected topline data from the VOXZOGO pivotal study in hypochondroplasia in 2026 and plans to submit applications in 2026 for a potential launch in 2027" https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-25-000049): "•In April 2025, BioMarin completed enrollment in its pivotal Phase 3 study with VOXZOGO in hypochondroplasia and the company is on track to share topline data in 2026, with a potential launch in 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/earningsrelease-1may25ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-25-000049): "(iii) expected topline data from the pivotal study in hypochondroplasia in 2026 and launch in 2027" https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/earningsrelease-1may25ex991.htm

### April 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypochondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06455059 (Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT06455059

### June 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Idiopathic Short Stature.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06382155 (A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT06382155

### Jul 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 3. Indication: hypochondroplasia.
- First seen 2026-08-06, last confirmed 2026-08-06.
- SEC Form 10-Q (accession 0001048477-26-000016): "•In July 2026, we submitted our supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia following our announcement in May 2026 that the Phase 3 CANOPY-HCH-3 study met its primary endpoint." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm

### August 6, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: achondroplasia.
- First seen 2026-08-06, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001048477-26-000015): "•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm
- SEC Form 10-Q (accession 0001048477-26-000023): "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm
- SEC Form 10-Q (accession 0001048477-26-000016): "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm

### September 16, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Noonan Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06668805 (A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-16 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT06668805

### February 28, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: achondroplasia.
- First seen 2026-08-06, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001048477-26-000023): "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm
- SEC Form 10-Q (accession 0001048477-26-000016): "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-26-000015): "•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-26-000021): "•BioMarin's application for full approval of VOXZOGO in children with achondroplasia is under review by the FDA, with a PDUFA target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm

### May 30, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: Hypochondroplasia.
- First seen 2026-11-02, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001048477-26-000021): "PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)" https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm
- SEC Form 10-Q (accession 0001048477-26-000023): "•In November 2026, we announced that the U.S. Food and Drug Administration (FDA) set a Prescription Drug User Fee Act (PDUFA) target action date of May 30, 2027 for supplemental new drug application (sNDA) to expand the use of VOXZOGO for the treatment of hypochondroplasia (HCH)." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001048477-26-000021): "•Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 30, 2027 for its supplemental NDA to expand the use of VOXZOGO for the treatment of HCH, the first potential targeted therapy for the condition." https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Achondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT02724228

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Achondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT02724228

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Achondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT04554940

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Achondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT04554940

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hypochondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT07126262

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hypochondroplasia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." https://clinicaltrials.gov/study/NCT07126262

## Same indication

- [TransCon (transcon)](https://sec-api.dev/pdufa/transcon) (ASND)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [May 2027](https://sec-api.dev/fda-calendar/2027-05), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vosoritide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VOXZOGO (vosoritide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vosoritide

```bibtex
@misc{secapidev_pdufa_vosoritide_20261116,
  title        = {VOXZOGO (vosoritide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vosoritide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vosoritide_20261116","title":"VOXZOGO (vosoritide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vosoritide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
